$NBIX
NEUROCRINE BIOSCIENCES INC

2020 Q3 Form 10-Q Financial Statement

#000091447520000036 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $258.5M $244.1M $222.1M
YoY Change 16.39% 85.64% 46.35%
Cost Of Revenue $2.700M $2.500M $2.200M
YoY Change 22.73% 66.67% 37.5%
Gross Profit $255.8M $241.5M $219.9M
YoY Change 16.33% 85.77% 46.4%
Gross Profit Margin 98.96% 98.93% 99.01%
Selling, General & Admin $112.5M $101.2M $84.50M
YoY Change 33.14% 46.67% 39.9%
% of Gross Profit 43.98% 41.9% 38.43%
Research & Development $69.10M $55.40M $45.30M
YoY Change 52.54% 41.69% 27.67%
% of Gross Profit 27.01% 22.94% 20.6%
Depreciation & Amortization $2.200M $2.100M $2.000M
YoY Change 10.0% 61.54% 100.0%
% of Gross Profit 0.86% 0.87% 0.91%
Operating Expenses $302.8M $195.3M $132.0M
YoY Change 129.39% 78.16% 35.48%
Operating Profit -$44.30M $46.20M $90.10M
YoY Change -149.17% 126.7% 65.86%
Interest Expense $8.500M -$10.10M $8.000M
YoY Change 6.25% 225.81% 4.28%
% of Operating Profit -21.86% 8.88%
Other Income/Expense, Net -$12.80M -$31.70M
YoY Change -59.62% 790.7%
Pretax Income -$57.10M $38.60M $58.40M
YoY Change -197.77% 105.32% 15.04%
Income Tax $500.0K $4.600M $4.600M
% Of Pretax Income 11.92% 7.88%
Net Earnings -$57.60M $34.00M $53.80M
YoY Change -207.06% 88.07% 5.98%
Net Earnings / Revenue -22.28% 13.93% 24.22%
Basic Earnings Per Share -$0.62 $0.37 $0.59
Diluted Earnings Per Share -$0.62 $0.35 $0.56
COMMON SHARES
Basic Shares Outstanding 93.30M shares 92.20M shares 91.90M shares
Diluted Shares Outstanding 93.30M shares 97.20M shares 96.10M shares

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $944.7M $670.5M $670.2M
YoY Change 40.97% 3.01% 5.49%
Cash & Equivalents $425.3M $112.3M $166.6M
Short-Term Investments $519.4M $558.2M $503.5M
Other Short-Term Assets $34.70M $16.60M $22.95M
YoY Change 51.17% -10.72% 21.45%
Inventory $20.60M $17.30M $10.80M
Prepaid Expenses
Receivables $156.9M $126.6M $115.3M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.157B $831.0M $819.2M
YoY Change 41.22% 12.64% 14.67%
LONG-TERM ASSETS
Property, Plant & Equipment $43.00M $41.90M $40.30M
YoY Change 6.69% 23.71% 40.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $225.1M $355.5M $253.7M
YoY Change -11.27% 64.58% 36.91%
Other Assets $3.400M $0.00 $4.700M
YoY Change -27.66% -100.0% -14.55%
Total Long-Term Assets $345.7M $475.0M $360.7M
YoY Change -4.16% 86.0% 64.44%
TOTAL ASSETS
Total Short-Term Assets $1.157B $831.0M $819.2M
Total Long-Term Assets $345.7M $475.0M $360.7M
Total Assets $1.503B $1.306B $1.180B
YoY Change 27.35% 31.5% 26.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $170.5M $141.3M $102.4M
YoY Change 66.5% 923.84% 42.22%
Accrued Expenses $9.700M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $425.0M $408.8M $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $611.0M $565.3M $115.7M
YoY Change 428.31% 540.69% -74.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $403.6M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $4.300M $17.10M $11.70M
YoY Change -63.24% -52.04% -60.75%
Total Long-Term Liabilities $4.300M $17.10M $11.70M
YoY Change -63.24% -52.04% -60.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $611.0M $565.3M $115.7M
Total Long-Term Liabilities $4.300M $17.10M $11.70M
Total Liabilities $698.3M $669.1M $605.4M
YoY Change 15.34% 30.59% 24.51%
SHAREHOLDERS EQUITY
Retained Earnings -$1.073B -$1.133B -$1.167B
YoY Change -8.01% -3.83% -2.44%
Common Stock $1.874B $1.768B $1.740B
YoY Change 7.75% 6.49% 5.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $804.3M $636.9M $574.5M
YoY Change
Total Liabilities & Shareholders Equity $1.503B $1.306B $1.180B
YoY Change 27.35% 31.5% 26.37%

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$57.60M $34.00M $53.80M
YoY Change -207.06% 88.07% 5.98%
Depreciation, Depletion And Amortization $2.200M $2.100M $2.000M
YoY Change 10.0% 61.54% 100.0%
Cash From Operating Activities -$17.50M $102.6M $97.80M
YoY Change -117.89% 103.17% 41.94%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K -$2.800M -$3.500M
YoY Change -88.57% -53.33% -71.77%
Acquisitions
YoY Change
Other Investing Activities $25.60M -$163.3M -$82.10M
YoY Change -131.18% 62.97% 150.3%
Cash From Investing Activities $25.20M -$166.2M -$85.60M
YoY Change -129.44% 56.5% 89.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.500M 7.300M 13.10M
YoY Change -80.92% 305.56% 142.59%
NET CHANGE
Cash From Operating Activities -17.50M 102.6M 97.80M
Cash From Investing Activities 25.20M -166.2M -85.60M
Cash From Financing Activities 2.500M 7.300M 13.10M
Net Change In Cash 10.20M -56.30M 25.30M
YoY Change -59.68% 4.45% -13.36%
FREE CASH FLOW
Cash From Operating Activities -$17.50M $102.6M $97.80M
Capital Expenditures -$400.0K -$2.800M -$3.500M
Free Cash Flow -$17.10M $105.4M $101.3M
YoY Change -116.88% 86.55% 24.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000914475
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
dei Document Type
DocumentType
10-Q
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
181400000 USD
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-22705
dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
12780 El Camino Real
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0525145
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
(858)
dei Local Phone Number
LocalPhoneNumber
617-7600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
NBIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
93429153 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
425300000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112300000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
517300000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
557300000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
519400000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
558200000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
156900000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
126600000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
20600000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
17300000 USD
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
34700000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
16600000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
1156900000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
831000000.0 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
180300000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
299300000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
299700000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
71000000.0 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
74300000 USD
CY2020Q3 us-gaap Equity Securities Fv Ni Restricted
EquitySecuritiesFvNiRestricted
43700000 USD
CY2019Q4 us-gaap Equity Securities Fv Ni Restricted
EquitySecuritiesFvNiRestricted
55900000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43000000.0 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41900000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3400000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2020Q3 us-gaap Assets
Assets
1502600000 USD
CY2019Q4 us-gaap Assets
Assets
1306000000.0 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
170500000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
141300000 USD
CY2020Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
425000000.0 USD
CY2019Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
408800000 USD
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15500000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15200000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
611000000.0 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
565300000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83000000.0 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
86700000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4300000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17100000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
698300000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
669100000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000.0 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000.0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000.0 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000.0 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93400000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93400000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92300000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92300000 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1874300000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1768100000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3200000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1400000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1073300000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1132700000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
804300000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
636900000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1502600000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1306000000.0 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
258500000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
222100000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
798000000.0 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
544000000.0 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2700000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2200000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4900000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7200000 USD
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
69100000 USD
CY2019Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
45300000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
208300000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
144700000 USD
CY2020Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
118500000 USD
CY2019Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
164500000 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
118100000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
112500000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
84500000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
326800000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
252800000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
302800000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
132000000.0 USD
us-gaap Costs And Expenses
CostsAndExpenses
706800000 USD
us-gaap Costs And Expenses
CostsAndExpenses
520500000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-44300000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
90100000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
91200000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
23500000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
8500000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
8000000.0 USD
us-gaap Interest Expense
InterestExpense
25000000.0 USD
us-gaap Interest Expense
InterestExpense
23800000 USD
CY2020Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-7000000.0 USD
CY2019Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-28500000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-12200000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-5800000 USD
CY2020Q3 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
2700000 USD
CY2019Q3 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
4800000 USD
nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
11000000.0 USD
nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
14000000.0 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12800000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31700000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26200000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15600000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57100000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
58400000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
65000000.0 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7900000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4600000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5600000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4900000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-57600000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
53800000 USD
us-gaap Net Income Loss
NetIncomeLoss
59400000 USD
us-gaap Net Income Loss
NetIncomeLoss
3000000.0 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1400000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1000000.0 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1800000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3600000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59000000.0 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
54800000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
61200000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6600000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93300000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93000000.0 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91400000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93300000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95200000 shares
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
831200000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-57600000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1400000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26700000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2500000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2900000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
804300000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
483700000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
53800000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000000.0 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20300000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13100000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2600000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
574500000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
636900000 USD
us-gaap Net Income Loss
NetIncomeLoss
59400000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1800000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
79000000.0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21600000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5600000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
804300000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
480800000 USD
us-gaap Net Income Loss
NetIncomeLoss
3000000.0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3600000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
54000000.0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000000.0 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5100000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
574500000 USD
us-gaap Net Income Loss
NetIncomeLoss
59400000 USD
us-gaap Net Income Loss
NetIncomeLoss
3000000.0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
79000000.0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
54000000.0 USD
us-gaap Depreciation
Depreciation
6400000 USD
us-gaap Depreciation
Depreciation
5400000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
15200000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
14100000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1000000.0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1000000.0 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-12200000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-5800000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1700000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-700000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
30300000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
57900000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3400000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-100000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
28100000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12300000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
29700000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-12400000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
139600000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
49500000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
399200000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
467100000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
557400000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
488800000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
54700000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6400000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11900000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
151800000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44900000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21600000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20000000.0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21600000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20000000.0 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
313000000.0 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24600000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115500000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147200000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
428500000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171800000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1100000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
100000 USD
us-gaap Interest Paid Net
InterestPaidNet
5800000 USD
us-gaap Interest Paid Net
InterestPaidNet
5800000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
400000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
500000 USD
nbix Number Of Irish Subsidiaries
NumberOfIrishSubsidiaries
2 subsidiary
CY2020Q3 us-gaap Debt Securities Available For Sale Accrued Interest Threshold Period Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff
P90D
us-gaap Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts
FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span>Accrued interest receivables on debt securities available-for-sale totaled $3.5 million at September 30, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September 30, 2020.
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
3500000 USD
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0 USD
CY2020Q3 nbix Debt Securities Available For Sale Position Number Of Positions
DebtSecuritiesAvailableForSalePositionNumberOfPositions
143 security
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
14 security
CY2020Q3 us-gaap Investments
Investments
1173000000.0 USD
CY2019Q4 us-gaap Investments
Investments
1029300000 USD
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14800000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14100000 USD
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1000000.0 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1500000 USD
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4800000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1700000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
20600000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
17300000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
425300000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112300000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
428500000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
115500000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
7400000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
5900000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
6400000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
5500000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y2M12D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2100000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
10600000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10900000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
11200000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11600000 USD
CY2020Q3 nbix Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
79700000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
126100000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
33400000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
92700000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9700000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83000000.0 USD
CY2020Q3 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced
28300000 USD
CY2020Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
517500000 USD
CY2019Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
517500000 USD
CY2020Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
5900000 USD
CY2019Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6900000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95200000 shares
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
101800000 USD
CY2020Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
425000000.0 USD
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93300000 shares
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
408800000 USD
CY2020Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
86600000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-57600000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
53800000 USD
us-gaap Net Income Loss
NetIncomeLoss
59400000 USD
us-gaap Net Income Loss
NetIncomeLoss
3000000.0 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93300000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93000000.0 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91400000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96100000 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.59
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03

Files In Submission

Name View Source Status
0000914475-20-000036-index-headers.html Edgar Link pending
0000914475-20-000036-index.html Edgar Link pending
0000914475-20-000036.txt Edgar Link pending
0000914475-20-000036-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nbix-20200930.htm Edgar Link pending
nbix-20200930.xsd Edgar Link pending
nbix-20200930exhibit311.htm Edgar Link pending
nbix-20200930exhibit312.htm Edgar Link pending
nbix-20200930exhibit32.htm Edgar Link pending
nbix-20200930_cal.xml Edgar Link unprocessable
nbix-20200930_def.xml Edgar Link unprocessable
nbix-20200930_htm.xml Edgar Link completed
nbix-20200930_lab.xml Edgar Link unprocessable
nbix-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending